Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-03-02 | Reverse | 1:10 |
| 2024-09-17 | Reverse | 1:20 |
| 2020-08-21 | Reverse | 1:10 |
Purple Biotech Ltd. is a clinical-stage Israeli company developing cancer therapies, including monoclonal antibody CM24 and small molecule NT219, targeting tumor immune evasion in various solid tumors.

IM1240, Purple Biotech’s tri-specific antibody from the CAPTN-3 platform, targets 5T4 to activate T cells and NK cells against solid tumors, aiming for a potent, safe, and broad anti-cancer immune response.
Overall rating: B-
| PEER | PRICE | |
|---|---|---|
AKTX | $7.85 | COMPARE |
REVB | $1.09 | COMPARE |
CDT | $2.86 | COMPARE |
DRMA | $1.42 | COMPARE |
XAGE | $0.28 | COMPARE |
PBM | $4.33 | COMPARE |
VINC | $0.01 | COMPARE |
SYRS | $0.00 | COMPARE |